Cerebrospinal fluid markers of inflammation and brain injury in Lyme neuroborreliosis – a prospective follow-up study

Ivar Tjernberg; Paula Gyllemark; Henrik Zetterberg; Kaj Blennow; Jan Ernerudh; Pia Forsberg; Johanna Sjöwall; Anna J. Henningsson

doi:10.1515/cclm-2022-0097

Artikel

Cerebrospinal fluid markers of inflammation and brain injury in Lyme neuroborreliosis – a prospective follow-up study

Ivar Tjernberg , Paula Gyllemark , Henrik Zetterberg , Kaj Blennow , Jan Ernerudh , Pia Forsberg , Johanna Sjöwall und Anna J. Henningsson

Veröffentlicht/Copyright: 2. Mai 2022

Veröffentlicht von

Veröffentlichen auch Sie bei De Gruyter Brill

Manuskript einreichen Informationen für Autor*innen

Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 60 Heft 7

Abstract

Objectives

The purpose of this study was to evaluate levels and kinetics of cerebrospinal fluid (CSF) markers of inflammation and brain injury in patients with Lyme neuroborreliosis (LNB).

Methods

Adult patients with clinically suspected LNB were enrolled, in a prospective clinical study in the South East of Sweden. Patients were classified according to the European Federation of Neurological Societies’ guidelines. Definite cases of LNB were re-examined one month later including a repeat CSF investigation. Routine laboratory parameters were investigated along with CSF levels of neurodegenerative markers glial fibrillary acidic protein (GFAp), total tau (t-tau) and neurofilament light protein (NFL), as well as neuroinflammatory markers soluble triggering receptor expressed on myeloid cells 2 (sTREM2), YKL-40 and CXCL13. Non-LNB served as controls. An additional comparison group consisted of spinal anesthesia subjects (SAS) without known central nervous system conditions.

Results

CSF levels of sTREM2 and CXCL13 were elevated in definite LNB patients at diagnosis compared with non-LNB patients (p<0.001) and SAS (p≤0.01). In addition, CSF levels of sTREM2, YKL-40 and CXCL13 rapidly declined in at follow-up after antibiotic treatment. In contrast, CSF levels of GFAp and t-tau did not differ across LNB groups, and did not change after treatment.

Conclusions

Although in a limited number of LNB patients, the results indicate a predominance of microglial and neuroinflammatory involvement rather than parenchymal CNS injury in CSF at diagnosis of LNB with a prompt decline after antibiotic treatment. The findings provide pathogenetic insights and may be of value in differential diagnosis of CSF findings.

Keywords: biomarkers; brain injury; cerebrospinal fluid; Lyme neuroborreliosis; pathogenesis

Corresponding author: Ivar Tjernberg, MD, PhD, Department of Clinical Chemistry and Transfusion Medicine, Region Kalmar County, Kalmar, Sweden; and Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, E-mail: ivar.tjernberg@liu.se

Funding source: Futurum - the Academy of Health and Welfare, Region Jönköping County

Funding source: AD Strategic Fund and the Alzheimer’s Association

Award Identifier / Grant number: #ADSF-21

Award Identifier / Grant number: #ADSF-21-831376-C

Award Identifier / Grant number: #ADSF-21-831381-C

Funding source: Svenska Läkaresällskapet

Funding source: Olav Thon Foundation

Funding source: Hjärnfonden

Award Identifier / Grant number: #FO2017-0243

Award Identifier / Grant number: #FO2019-0228

Funding source: Forskningsrådet i sydöstra Sverige

Funding source: Alzheimer's Association 2021 Zenith Award

Award Identifier / Grant number: ZEN-21-848495

Funding source: European Union Joint Program for Neurodegenerative Disorders

Award Identifier / Grant number: JPND2019-466-236

Funding source: H2020 European Research Council

Award Identifier / Grant number: #681712

Funding source: Alzheimer Drug Discovery Foundation (ADDF), USA

Award Identifier / Grant number: #201809-2016862

Award Identifier / Grant number: #RDAPB-201809-2016615

Funding source: UK Dementia Research Institute at UCL

Funding source: Swedish State Support for Clinical Research

Award Identifier / Grant number: #ALFGBG-715986

Award Identifier / Grant number: #ALFGBG-720931

Award Identifier / Grant number: #RÃ–-936276

Funding source: European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement

Award Identifier / Grant number: No 860197 (MIRIADE)

Funding source: National Institute of Health (NIH), USA

Award Identifier / Grant number: #1R01AG068398-01

Funding source: Familjen Erling-Perssons Stiftelse

Funding source: Swedish Alzheimer Foundation

Award Identifier / Grant number: #AF-742881

Funding source: Vetenskapsrådet

Award Identifier / Grant number: #2017-00915

Award Identifier / Grant number: #2018-02532

Award Identifier / Grant number: #2018-02776

Funding source: Stiftelsen för Gamla Tjänarinnor, Sweden

Award Identifier / Grant number: #FO2019-0228

Acknowledgments

We thank all involved patients and healthcare and laboratory staff for valuable assistance.

Research funding: This study was conducted with support from the Swedish Society of Medicine, the Medical Research Council of South East Sweden (FORSS) and Futurum – the Academy of Health and Welfare, Region Jönköping County. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the National Institute of Health (NIH), USA, (grant #1R01AG068398-01), and the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495). JE is supported by the Swedish Research Council (2018-02776), the Medical Inflammation and Infection Centre (MIIC), and ALF grants Region Östergötland (RÖ-936276).
Author contribution: IT had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: IT, HZ, KB, JE, AJH. Acquisition of data: IT, PG, JS, HZ, KB, JE, PF, AJH. Analysis and interpretation of data: IT, PG, JS. Laboratory analyses: HZ, KB. Drafting of the manuscript: IT, PG, JS. Critical revision of the manuscript for important intellectual content: IT, PG, JS, HZ, KB, JE, PF, AJH. Statistical analysis: IT. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: IT has served at advisory board for Pfizer Inc. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper. JE has given lectures, unrelated to the present work, in symposia sponsored by Merck, Biogen och Abbvie. JS has given lectures and participated in advisory boards in collaboration with Merck and Biogen. PG and PF report no conflicts of interest. AJH has a collaborative research agreement with Abbott Laboratories, Chicago, IL and Reagena Ltd, Toivala, Finland.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: Written consent was obtained from all participants before study inclusion. The study conforms with World Medical Association Declaration of Helsinki and was approved by the Regional Ethical Review Board in Linköping, Sweden (Dnr M106-04, 2011/65-32, 2015/192-32, 2018/388-32, 2019-02449).

References

1. Stanek, G, Wormser, GP, Gray, J, Strle, F. Lyme borreliosis. Lancet 2012;379:461–73. https://doi.org/10.1016/s0140-6736(11)60103-7.Suche in Google Scholar

2. Steere, AC, Strle, F, Wormser, GP, Hu, LT, Branda, JA, Hovius, JW, et al.. Lyme borreliosis. Nat Rev Dis Prim 2016;2:16090. https://doi.org/10.1038/nrdp.2016.90.Suche in Google Scholar PubMed PubMed Central

3. Koedel, U, Fingerle, V, Pfister, HW. Lyme neuroborreliosis-epidemiology, diagnosis and management. Nat Rev Neurol 2015;11:446–56. https://doi.org/10.1038/nrneurol.2015.121.Suche in Google Scholar PubMed

4. Stanek, G, Strle, F. Lyme borreliosis-from tick bite to diagnosis and treatment. FEMS Microbiol Rev 2018;42:233–58. https://doi.org/10.1093/femsre/fux047.Suche in Google Scholar PubMed

5. Mygland, A, Ljostad, U, Fingerle, V, Rupprecht, T, Schmutzhard, E, Steiner, I, et al.. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 2010;17:8–16,e1–4. https://doi.org/10.1111/j.1468-1331.2009.02862.x.Suche in Google Scholar PubMed

6. Berglund, J, Stjernberg, L, Ornstein, K, Tykesson-Joelsson, K, Walter, H. 5-y Follow-up study of patients with neuroborreliosis. Scand J Infect Dis 2002;34:421–5. https://doi.org/10.1080/00365540110080421.Suche in Google Scholar PubMed

7. Dotevall, L, Hagberg, L, Karlsson, JE, Rosengren, LE. Astroglial and neuronal proteins in cerebrospinal fluid as markers of CNS involvement in Lyme neuroborreliosis. Eur J Neurol 1999;6:169–78. https://doi.org/10.1111/j.1468-1331.1999.tb00010.x.Suche in Google Scholar PubMed

8. Mila-Aloma, M, Salvado, G, Gispert, JD, Vilor-Tejedor, N, Grau-Rivera, O, Sala-Vila, A, et al.. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer’s continuum. Alzheimers Dement 2020;16:1358–71. https://doi.org/10.1002/alz.12131.Suche in Google Scholar PubMed PubMed Central

9. McGrowder, DA, Miller, F, Vaz, K, Nwokocha, C, Wilson-Clarke, C, Anderson-Cross, M, et al.. Cerebrospinal fluid biomarkers of Alzheimer’s disease: current evidence and future perspectives. Brain Sci 2021;11:1–56. https://doi.org/10.3390/brainsci11020215.Suche in Google Scholar PubMed PubMed Central

10. Rupprecht, TA, Manz, KM, Fingerle, V, Lechner, C, Klein, M, Pfirrmann, M, et al.. Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systematic review and meta-analysis. Clin Microbiol Infect 2018;24:1234–40. https://doi.org/10.1016/j.cmi.2018.04.007.Suche in Google Scholar PubMed

11. Teunissen, C, Menge, T, Altintas, A, Alvarez-Cermeno, JC, Bertolotto, A, Berven, FS, et al.. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 2013;19:1802–9. https://doi.org/10.1177/1352458513488232.Suche in Google Scholar

12. Gaetani, L, Hoglund, K, Parnetti, L, Pujol-Calderon, F, Becker, B, Eusebi, P, et al.. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimer’s Res Ther 2018;10:8. https://doi.org/10.1186/s13195-018-0339-1.Suche in Google Scholar

13. Rosengren, LE, Ahlsen, G, Belfrage, M, Gillberg, C, Haglid, KG, Hamberger, A. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of children. J Neurosci Methods 1992;44:113–9. https://doi.org/10.1016/0165-0270(92)90004-w.Suche in Google Scholar

14. Jensen, CS, Bahl, JM, Ostergaard, LB, Hogh, P, Wermuth, L, Heslegrave, A, et al.. Exercise as a potential modulator of inflammation in patients with Alzheimer’s disease measured in cerebrospinal fluid and plasma. Exp Gerontol 2019;121:91–8. https://doi.org/10.1016/j.exger.2019.04.003.Suche in Google Scholar

15. Swedish Medical Products Agency. Läkemedelsbehandling av borreliainfektion - ny rekommendation. Läkemedelsverket, editor. Läkemedelsverket; 2009. p. 12–7.Suche in Google Scholar

16. Piccio, L, Buonsanti, C, Cella, M, Tassi, I, Schmidt, RE, Fenoglio, C, et al.. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain 2008;131:3081–91. https://doi.org/10.1093/brain/awn217.Suche in Google Scholar

17. Zetterberg, H. Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis. Acta Neurol Scand 2017;136(201 Suppl):15–7. https://doi.org/10.1111/ane.12845.Suche in Google Scholar

18. Duray, PH. Histopathology of clinical phases of human Lyme disease. Rheum Dis Clin N Am 1989;15:691–710. https://doi.org/10.1016/s0889-857x(21)01023-1.Suche in Google Scholar

19. Fallon, BA, Levin, ES, Schweitzer, PJ, Hardesty, D. Inflammation and central nervous system Lyme disease. Neurobiol Dis 2010;37:534–41. https://doi.org/10.1016/j.nbd.2009.11.016.Suche in Google Scholar PubMed

20. Dotevall, L, Rosengren, LE, Hagberg, L. Increased cerebrospinal fluid levels of glial fibrillary acidic protein (GFAp) in Lyme neuroborreliosis. Infection 1996;24:125–9. https://doi.org/10.1007/bf01713316.Suche in Google Scholar

Received: 2022-02-04

Revised: 2022-04-20

Accepted: 2022-04-20

Published Online: 2022-05-02

Published in Print: 2022-06-27

Sie haben derzeit keinen Zugang zu diesem Inhalt.

Artikel in diesem Heft

https://doi.org/10.1515/cclm-2022-0097

Schlagwörter für diesen Artikel

biomarkers; brain injury; cerebrospinal fluid; Lyme neuroborreliosis; pathogenesis